HRT Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

HRT Financial’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,300	Closed	-$8.12M	–	2970
2023 Q2	$8.12M	Buy	11,300 +6,800	+151%	+$5.24M	0.08%	183
2023 Q1	$3.7M	Buy	+4,500	New	+$3.39M	0.05%	342
2022 Q3	–	Sell	-700	Closed	-$413K	–	3377
2022 Q2	$413K	Buy	+700	New	+$455K	﹤0.01%	1808
2021 Q4	–	Sell	-2,600	Closed	-$1.57M	–	3923
2021 Q3	$1.57M	Buy	+2,600	New	+$1.61M	0.01%	889
2021 Q2	–	Sell	-6,900	Closed	-$3.26M	–	3415
2021 Q1	$3.26M	Buy	+6,900	New	+$3.36M	0.03%	391
2020 Q4	–	Sell	-3,400	Closed	-$1.9M	–	2349
2020 Q3	$1.9M	Buy	+3,400	New	+$2.06M	0.06%	262
2018 Q4	–	Sell	-2,500	Closed	-$1.01M	–	728
2018 Q3	$1.01M	Buy	+2,500	New	+$951K	0.16%	101

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HRT Financial's REGN Position: Q4 2025 in Review

HRT Financial sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 98,849 shares — an estimated $67.1M sold.

HRT Financial first reported a position in REGN in Q3 2015 and held it in 17 quarters. The position peaked at $55.6M in Q3 2025. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

HRT Financial reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
HRT Financial sold 98,849 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $67.1M.
HRT Financial first reported a position in Regeneron Pharmaceuticals in Q3 2015 and held it in 17 quarters.
HRT Financial's Regeneron Pharmaceuticals position peaked at $55.6M in Q3 2025.
1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.